Literature DB >> 16793843

Influence of human leucocyte antigen-DRB1 on the susceptibility to rheumatoid arthritis and on the production of anti-cyclic citrullinated peptide antibodies in a Portuguese population.

D Ligeiro1, J E Fonseca, O Abade, I Abreu, M Cruz, P Nero, J Cavaleiro, J Teles, H Trindade, J M Caetano, J Branco.   

Abstract

OBJECTIVE: To clarify the influence of the HLA-DRB1 locus on the susceptibility to rheumatoid arthritis and the production of anti-cyclic citrullinated peptide antibodies (anti-CCP) in a Portuguese population.
METHODS: 141 patients with rheumatoid arthritis fulfilling the American College of Rheumatology 1987 revised criteria for rheumatoid arthritis were compared with 150 healthy controls. Human leucocyte antigen (HLA)-DRB1 locus genotyping was assessed by polymerase chain reaction reverse probing assays and sequence-specific primers. Anti-CCP antibodies were quantified by ELISA in patients with rheumatoid arthritis. Frequencies between groups were compared by the two-sided Fisher's exact test and considered significant if p<0.05.
RESULTS: The HLA-DRB1*04 and HLA-DRB1*10 groups were highly associated with rheumatoid arthritis (p<0.001 and p = 0.031, respectively). High titres of anti-CCP antibodies were largely associated with the presence of HLA-DRB1*04/10.
CONCLUSION: The well-recognised susceptibility alleles to rheumatoid arthritis, HLA-DRB1*04, were associated with rheumatoid arthritis in Portuguese patients. The relatively rare DRB1*10 was also associated with rheumatoid arthritis, as was described previously in other southern European countries. Both groups were associated with high anti-CCP titres, reinforcing its relevance to disease onset.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16793843      PMCID: PMC1798513          DOI: 10.1136/ard.2005.051177

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  15 in total

1.  Severity of rheumatoid arthritis in Portuguese patients: comment on the article by Drosos et al and on the letter by Ronda et al.

Authors:  J E Fonseca; H Canhão; F Costa Dias; M J Leandro; C Resende; J C Teixeira da Costa; J A Pereira da Silva; M Viana Queiroz
Journal:  Arthritis Rheum       Date:  2000-02

2.  Ethnic variation in the clinical manifestations of rheumatoid arthritis: role of HLA-DRB1 alleles.

Authors:  Inmaculada Del Rincón; Daniel F Battafarano; Ramón A Arroyo; Frederick T Murphy; Michael Fischbach; Agustín Escalante
Journal:  Arthritis Rheum       Date:  2003-04-15

Review 3.  The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis.

Authors:  P K Gregersen; J Silver; R J Winchester
Journal:  Arthritis Rheum       Date:  1987-11

4.  Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins.

Authors:  Tom W J Huizinga; Christopher I Amos; Annette H M van der Helm-van Mil; Wei Chen; Floris A van Gaalen; Damini Jawaheer; Geziena M T Schreuder; Mark Wener; Ferdinand C Breedveld; Naila Ahmad; Raymond F Lum; Rene R P de Vries; Peter K Gregersen; Rene E M Toes; Lindsey A Criswell
Journal:  Arthritis Rheum       Date:  2005-11

5.  Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule.

Authors:  Jonathan A Hill; Scott Southwood; Alessandro Sette; Anthony M Jevnikar; David A Bell; Ewa Cairns
Journal:  J Immunol       Date:  2003-07-15       Impact factor: 5.422

6.  Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis.

Authors:  Solbritt Rantapää-Dahlqvist; Ben A W de Jong; Ewa Berglin; Göran Hallmans; Göran Wadell; Hans Stenlund; Ulf Sundin; Walther J van Venrooij
Journal:  Arthritis Rheum       Date:  2003-10

7.  Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis.

Authors:  Floris A van Gaalen; Jill van Aken; Tom W J Huizinga; Geziena M Th Schreuder; Ferdinand C Breedveld; Eric Zanelli; Walther J van Venrooij; Cornelis L Verweij; René E M Toes; René R P de Vries
Journal:  Arthritis Rheum       Date:  2004-07

8.  HLA-DR4 antigen and IgM rheumatoid factors.

Authors:  M V Queirós; M R Sancho; J M Caetano
Journal:  J Rheumatol       Date:  1982 May-Jun       Impact factor: 4.666

9.  Occurrence of rheumatoid arthritis in a nationwide series of twins.

Authors:  K Aho; M Koskenvuo; J Tuominen; J Kaprio
Journal:  J Rheumatol       Date:  1986-10       Impact factor: 4.666

10.  Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study.

Authors:  F A van Gaalen; S P Linn-Rasker; W J van Venrooij; B A de Jong; F C Breedveld; C L Verweij; R E M Toes; T W J Huizinga
Journal:  Arthritis Rheum       Date:  2004-03
View more
  2 in total

1.  TRAF1/C5 but not PTPRC variants are potential predictors of rheumatoid arthritis response to anti-tumor necrosis factor therapy.

Authors:  Helena Canhão; Ana Maria Rodrigues; Maria José Santos; Diana Carmona-Fernandes; Bruno F Bettencourt; Jing Cui; Fabiana L Rocha; José Canas Silva; Joaquim Polido-Pereira; José Alberto Pereira Silva; José António Costa; Domingos Araujo; Cândida Silva; Helena Santos; Cátia Duarte; Rafael Cáliz; Ileana Filipescu; Fernando Pimentel-Santos; Jaime Branco; Juan Sainz; Robert M Plenge; Daniel H Solomon; Jácome Bruges-Armas; José António P Da Silva; João Eurico Fonseca; Elizabeth W Karlson
Journal:  Biomed Res Int       Date:  2015-03-05       Impact factor: 3.411

2.  Interaction between smoking and HLA-DRB1*04 gene is associated with a high cardiovascular risk in Brazilian Amazon patients with rheumatoid arthritis.

Authors:  Narjara de Oliveira Boechat; Mauricio Morish Ogusku; Antonio Luiz Boechat; Aya Sadahiro
Journal:  PLoS One       Date:  2012-08-13       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.